Novel Central Nervous System Drug Delivery Systems

2014 ◽  
Vol 83 (5) ◽  
pp. 507-520 ◽  
Author(s):  
Jocelyn Stockwell ◽  
Nabiha Abdi ◽  
Xiaofan Lu ◽  
Oshin Maheshwari ◽  
Changiz Taghibiglou
2016 ◽  
Vol 21 (3) ◽  
pp. 272-283 ◽  
Author(s):  
Guilong Zhang ◽  
Lukui Chen ◽  
Xiaoyuan Guo ◽  
Ahsan Khan ◽  
Yuchun Gu ◽  
...  

2021 ◽  
Vol 17 (8) ◽  
pp. 1459-1485
Author(s):  
Mengyao Wang ◽  
Ying Qu ◽  
Danrong Hu ◽  
Ting Niu ◽  
Zhiyong Qian

Primary central nervous system lymphoma (PCNSL) is a rare but highly aggressive subtype of extra nodal non-Hodgkin lymphoma (NHL), which is confined in the central nervous system (CNS). Despite recent advancements in treatment options, the overall prognosis of PCNSL remains poor. Among many unfavorable factors affecting efficacy, inadequate drug delivery into the CNS is still the thorniest challenge. Blood-brain barrier (BBB) constitutes a significant impediment, restricting entry of most therapeutics to the brain. Nanotechnology has offered great promise for brain diseases, as various nano-based drug delivery systems (NDDSs) have been developed for delivery of theranostic agents in to the CNS. These drug delivery systems possess significant advantages, including good feasibility, reliable safety profile, excellent BBB penetration and potent antitumor effects. As for treatment of PCNSL, numerous well-developed BBB-crossing nano-based strategies can be applied with proper modifications and improvements. Some exquisitely designed NDDSs specific for PCNSL have shown great potential. In this review, we provide a summary on current status of diagnosis and treatment of PCNSL, followed by an overview of BBB-crossing strategies applied in management of PCNSL, both novel and wellestablished. Finally, challenges and future perspectives in this field are also discussed.


2020 ◽  
Vol 12 (19) ◽  
pp. 1759-1778
Author(s):  
Bikram Khadka ◽  
Jae-Young Lee ◽  
Ki-Taek Kim ◽  
Jong-Sup Bae

Most therapeutics for the treatment of traumatic central nervous system injuries, such as traumatic brain injury and spinal cord injury, encounter various obstacles in reaching the target tissue and exerting pharmacological effects, including physiological barriers like the blood–brain barrier and blood–spinal cord barrier, instability rapid elimination from the injured tissue or cerebrospinal fluid and off-target toxicity. For central nervous system delivery, nano- and microdrug delivery systems are regarded as the most suitable and promising carriers. In this review, the pathophysiology and biomarkers of traumatic central nervous system injuries (traumatic brain injury and spinal cord injury) are introduced. Furthermore, various drug delivery systems, novel combinatorial therapies and advanced therapies for the treatment of traumatic brain injury and spinal cord injury are emphasized.


Sign in / Sign up

Export Citation Format

Share Document